

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

IMAGE TECHNOLOGY LABORATORIES INC
Form 10QSB
November 20, 2007

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-QSB

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the quarterly period ended September 30, 2007 or

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 34-00031307

IMAGE TECHNOLOGY LABORATORIES, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

22-3531373

(State or Other Jurisdiction
of Incorporation or Organization)

(IRS Employer
Identification No.)

602 Enterprise Drive
Kingston, New York 12401

(Address of Principal Executive Offices)

(845) 338-3366

(Registrant's Telephone Number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. YES NO

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 20, 2007, there were 15,238,778 shares of the registrant's common stock outstanding.

IMAGE TECHNOLOGY LABORATORIES, INC.

INDEX

	PAGE NO.
PART I - FINANCIAL INFORMATION	2
Item 1 - Financial Statements	2
Condensed Balance Sheets	3
Condensed Statements of Operations	4

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

Condensed Statement of Changes in Stockholders' Deficiency	5
Condensed Statements of Cash Flows	6
Notes to Condensed Financial Statements	7
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations	10
Item 3 - Controls and Procedures	16
PART II - OTHER INFORMATION	17
Item 1 - Legal Proceedings	17
Item 2 - Changes in Securities	17
Item 3 - Defaults Upon Senior Securities	17
Item 4 - Submission of Matters to a Vote of Security Holders	17
Item 5 - Other Information	17
Item 6 - Exhibits and Reports on Form 8-K	18
SIGNATURES	19
EXHIBIT 31.1 - CERTIFICATION	20
EXHIBIT 32.1 - ADDITIONAL CERTIFICATION	21

2

IMAGE TECHNOLOGY LABORATORIES, INC.

PART I - FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

CONDENSED BALANCE SHEETS

SEPTEMBER 30, 2007
(UNAUDITED)

ASSETS

CURRENT ASSETS:

Cash and cash equivalents	404,420
Accounts receivable	110,833
Prepaid expenses and other current assets	8,637

TOTAL CURRENT ASSETS	523,890
----------------------	---------

Equipment and improvements, net	155,561
Rent - deposit	1,496

TOTAL ASSETS	680,947
--------------	---------

LIABILITIES AND STOCKHOLDERS' DEFICIENCY

CURRENT LIABILITIES:

Loan payable to stockholder	\$ 0
Loan: Bank line of credit	68,316
Current portion of long-term debt	109,180
Accounts payable and accrued expenses	196,796
Accrued compensation payable to stockholders	113,597

TOTAL CURRENT LIABILITIES	487,889
---------------------------	---------

Long-term debt, less current portion	515,101
Notes payable to stockholders, less current portion	3,684

TOTAL LIABILITIES	1,006,674
-------------------	-----------

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

STOCKHOLDERS' DEFICIENCY:		-----
Preferred stock, par value \$.01 per share; 5,000,000 shares authorized; 1,500,000 shares issued and outstanding, Series A	15,000	
1,037 and 1,000 shares issued and outstanding, Cumulative Convertible Series B	15,994	
Common stock, par value \$.01 per share; 50,000,000 shares authorized; 15,238,778 shares authorized and outstanding	152,388	
Additional paid-in capital	3,703,463	
Accumulated deficit	(4,212,571)	

TOTAL STOCKHOLDERS' DEFICIENCY	(325,727)	

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	\$ 680,947	=====

The accompanying notes are an integral part of the financial statements.

IMAGE TECHNOLOGY LABORATORIES, INC.

CONDENSED STATEMENTS OF OPERATIONS
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)

	THREE MONTHS ENDED SEPTEMBER 30,		NINE ENDING SE
	2007	2006	2007
	----	----	----
REVENUE:			
Systems/ software: license fees and sales	\$ 131,114	\$ 98,786	\$ 338,478
Dividend Income	5,087	0	5,087
Service Income		2,000	256
	-----	-----	-----
TOTAL REVENUE	136,201	100,786	343,821
COST OF REVENUE:	4,209	1,067	5,150
	-----	-----	-----
GROSS PROFIT	131,992	99,719	338,671
	-----	-----	-----
COSTS AND EXPENSES:			
Research and development	103,853	93,196	285,002
Sales and marketing	4,154	3,788	11,518
General and administrative (includes interest expense of \$24,018 and \$26,388 for the nine months ending September 30, 2007 and 2006, respectively; \$17,314 and \$8,990 for the three months ending September 30,2007 and 2006 respectively)	114,828	34,240	240,325
Stock based compensation	24,483	24,483	73,448
	-----	-----	-----

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

TOTAL COSTS AND EXPENSES	247,318	155,707	610,293
	-----	-----	-----
NET INCOME (LOSS)	\$ (115,326)	\$ (55,988)	\$ (271,622)
	=====	=====	=====
NET (LOSS) PER COMMON SHARE:			
Basic and diluted	\$ (0.01)	\$ (0.00)	\$ (0.02)
AVERAGE NUMBER OF SHARES USED IN COMPUTATION:			
Basic and diluted	16,739,778	16,739,778	16,739,778
	=====	=====	=====

The accompanying notes are an integral part of the financial statements.

4

IMAGE TECHNOLOGY LABORATORIES, INC.

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIENCY
NINE MONTHS ENDED SEPTEMBER 30, 2007
(UNAUDITED)

	PREFERRED STOCK, ALL SERIES		COMMON STOCK		ADD TION PAID CAPI
	NUMBER OF SHARES	AMOUNT	NUMBER OF SHARES	AMOUNT	
	-----	-----	-----	-----	-----
Balance, January 1, 2007	1,501,000	\$15,010	15,238,778	\$152,388	\$3,637
Stock based compensation					
Cumulative Convertible Preferred Series B, dividend Accumulation	37	15,984			
	-----	-----	-----	-----	-----
Net loss					
	-----	-----	-----	-----	-----
Balance, September 30, 2007	1,501,037	\$30,994	15,238,778	\$ 152,388	\$3,677
	=====	=====	=====	=====	=====

The accompanying notes are an integral part of the financial statements.

5

IMAGE TECHNOLOGY LABORATORIES, INC.

CONDENSED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006
(UNAUDITED)

NINE MONTHS

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

	ENDED SEPTEMBER	

	2007	2006
OPERATING ACTIVITIES:		
Net loss	\$ (271,622)	\$ (1,000,000)
Adjustments to reconcile net loss to net cash		
Provided (used) in operating activities:		
Depreciation and amortization of equipment and improvements	42,408	
Stock based compensation	73,448	
Changes in operating assets and liabilities:		
Accounts receivable	84,005	
Prepaid expenses and other current assets	1,966	
Accounts payable and accrued expenses	(20,606)	
Accrued compensation payable to stockholders	(8,126)	
	-----	-----
NET CASH PROVIDED (USED) IN OPERATING ACTIVITIES	(98,527)	(1,000,000)
	-----	-----
INVESTING ACTIVITIES - purchase of equipment and improvements	(79,702)	
	-----	-----
FINANCING ACTIVITIES:		
Proceeds from (repayment of) bank line of credit	1,421	
Proceeds from private placement of common stock	0	2,000,000
Redemption of common stock	0	(2,000,000)
Proceeds from notes payable and long-term debt	624,281	
Proceeds from loans from stockholders	3,684	2,000,000
Repayments of notes payable and long-term debt	(50,000)	(1,000,000)
	-----	-----
NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES	579,386	1,000,000
	-----	-----
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	401,157	(1,000,000)
	-----	-----
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	3,263	
	-----	-----
CASH AND CASH EQUIVALENTS, END OF PERIOD	\$ 404,420	\$ 3,263
	=====	=====
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:		
Interest paid	\$ 24,018	\$ 24,018
	=====	=====
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:		
Conversion of notes payable to stockholders to Preferred Stock Series B	\$ 0	\$ 3,000,000
	=====	=====

The accompanying notes are an integral part of the financial statements.

IMAGE TECHNOLOGY LABORATORIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

NOTE 1 - BASIS OF PRESENTATION:

In the opinion of management, the accompanying unaudited condensed financial statements reflect all adjustments, consisting of normal recurring accruals, necessary to present fairly the financial position of Image Technology Laboratories, Inc. (the "Company") as of September 30, 2007, its results of

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

operations for the three and nine months ended September 30, 2007 and 2006, changes in stockholders' deficiency for the nine months ended September 30, 2007 and cash flows for the nine months ended September 30, 2007 and 2006. Certain terms used herein are defined in the audited financial statements of the Company as of December 31, 2006 and for the years ended December 31, 2006 and 2005 (the "Audited Financial Statements") included in the Company's Annual Report on Form 10-KSB previously filed with the Securities and Exchange Commission (the "SEC"). Pursuant to rules and regulations of the SEC, certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed in or omitted from these financial statements unless significant changes have taken place since the end of the most recent fiscal year. Accordingly, the accompanying unaudited condensed financial statements should be read in conjunction with the Audited Financial Statements and the other information included in the Form 10-KSB.

The results of operations for the three and nine months ended September 30, 2007 are not necessarily indicative of the results of operations to be expected for the full year ending December 31, 2007.

These unaudited financial statements have been prepared assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. The Company's independent registered public accounting firm's report on the financial statements included in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, contained an explanatory paragraph regarding the Company's ability to continue as a going concern.

NOTE 2 - EARNINGS (LOSS) PER SHARE:

The Company presents "basic" earnings (loss) per common share and, if applicable, "diluted" earnings (loss) per common share pursuant to the provisions of Statement of Financial Accounting Standards No. 128, "Earnings per Share" ("SFAS 128"). Basic earnings (loss) per common share are calculated by dividing net income or loss applicable to common stock by the weighted average number of common shares outstanding during each period. The calculation of diluted earnings (loss) per common share is similar to that of basic earnings (loss) per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and warrants, were issued during the period. The rights of the Company's preferred and common stockholders are substantially equivalent. The Company has included the 1,501,000 Preferred Series A shares and the 1,037 Cumulative Convertible Preferred Series B shares outstanding in the weighted average number of common shares outstanding in the computation of basic loss per share for the year ended December 31, 2006 in accordance with the "two class" method of computing earnings (loss) per share set forth in SFAS 128.

The Company had a net loss for the three months ended September 30, 2007 and net losses for the nine months ended September 30, 2007 and 2006, and a net gain for the three months ended September 30, 2006. The assumed effects of the exercise of vested options to purchase 1,850,000 and 1,400,000 common shares at September 30, 2007 and 2006, respectively, and warrants to purchase 230,000 common shares outstanding at September 30, 2007 would be anti-dilutive or insignificant and, therefore, they have not been considered in the calculations of diluted per share amounts in the accompanying condensed statements of operations for those periods.

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

IMAGE TECHNOLOGY LABORATORIES, INC.

NOTE 3 - WORKING CAPITAL LOAN AGREEMENT:

During September 2002, the Company entered into a one-year working capital loan agreement with a financial institution for borrowings of up to \$75,000. The agreement automatically renews annually unless one of the parties gives appropriate notice for cancellation. Outstanding borrowings bear interest payable monthly at 1% above the prime rate, and are guaranteed by the Estate of the Company's principal stockholder, Dr. David Ryon. At September 30, 2007, there was \$68,316 outstanding under this agreement.

In June 2007, the Company entered into a five-year Accounts Receivable loan agreement with PowerLease Solutions, LLC and NetBank to borrow \$650,000 at a 9.5% annual interest rate. Monthly payments are \$13,651 and the loan is co-signed by the Company's principal stockholder. As of September 30, 2007, there was \$624,281 outstanding under this agreement. Fixed fees payable to PowerLease were \$10,402.

NOTE 4 - NOTES PAYABLE TO STOCKHOLDERS:

During November and December 2004, Dr. David Ryon, the Company's principal stockholder, President, and Chief Executive Officer, until his death in December 2004, loaned the Company an aggregate of \$105,000. In December 2004, to memorialize this loan, he executed, as President and Chief Executive Officer, on behalf of the Company, a demand promissory note payable to himself and bearing interest at 10% per annum. He also executed a security agreement, for himself on behalf of the Company, granting to himself a security interest in all of the Company's assets not previously encumbered as security for full payment under the note. Prior to April 12, 2005, the Company negotiated with the Estate of Dr. David Ryon a 24-month payment schedule, beginning in January 2006. The Company's Board of Directors approved the revised terms of the promissory note on April 12, 2005. In December 2005, the Estate of Dr. Ryon loaned the Company an additional \$36,000 under an amendment to the December 2004 promissory note and the payment schedule was renegotiated to begin in January 2007. Additional amounts were loaned to the Company in March 2006 for \$22,500, in August 2006 for \$57,672 and in September 2006 for \$153,375. These amounts, along with other previous loans to the Company by the largest stockholder totaling \$374,548 were converted to 1000 shares of Cumulative Convertible Preferred Stock Series B in late September 2006, and all accrued interest was forgiven. Cumulative Convertible Preferred Stock Series B can be converted to common stock of Image Technology Laboratories at a ratio of one share of Cumulative Convertible Preferred Stock Series B to 2,700 shares of common stock. Either the stockholder or the Company may elect to force conversion after two years in units of 100 shares of Cumulative Convertible Preferred Stock Series B. The Company may also elect to repurchase the Cumulative Convertible Preferred Stock Series B in units of 100 shares of Cumulative Convertible Preferred Stock Series B at any time for \$432 per share of Cumulative Convertible Preferred Stock Series B. Fixed dividend is accumulated as 12.5 additional shares of Cumulative Convertible Preferred Stock Series B per quarter. The underlying common stock, should the Company or shareholder elect to convert, is unregistered. The voting rights are set at one vote per share of Cumulative Convertible Preferred Stock Series B.

In September 2005, the Company received a total of \$50,000 in cash as part of a Bridge Loan Agreement that included the issuance of warrants to purchase 50,000 shares of Common Stock of the Company. All \$50,000 of these funds came from a member of the Company's Board of Directors. The five-year warrants have an exercise price of \$0.33 per share. The Bridge Loan has an annual interest rate of 14%, a maturity of 12 months and can be prepaid upon certain events such as receipt of a certain level of funds from the InMed Services agreement and gross proceeds of equity financing above \$500,000. The principal of \$50,000 and part of the accrued interest was repaid in July 2007 and the remaining accrued

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

interest of \$5,000 associated with this loan is still outstanding.

8

IMAGE TECHNOLOGY LABORATORIES, INC.

NOTE 5 - STOCK OPTIONS

The Company did not grant any options under the Company's option plan during the quarter ended September 30, 2007.

Prior to January 1, 2006 the Company measured compensation cost related to stock options issued to employees using the intrinsic value method of accounting prescribed by Accounting Principles Board Opinion No. 25 ("APB 25"), "Accounting For Stock Issued To Employees". The Company has adopted the provisions of Statement of Financial Accounting Standards No. 123R ("SFAS 123R"), "Accounting For Stock-Based Compensation." As a result of SFAS 123R, the Company began expensing the fair value of employee stock options over the vesting period beginning with its fiscal quarter ending March 31, 2006. For the quarter ending September 30, 2007, the Company expensed \$24,483 due to stock options.

NOTE 6 - WARRANTS

As of September 30, 2007, the Company had 230,000 warrants outstanding at an exercise price of \$0.33 per share. The warrants expire in 2010.

NOTE 7 - FIXED DIVIDENDS

The Company's largest stockholder accumulated 12 additional shares of Cumulative Convertible Preferred Stock Series B on January 1, 2007 as Fixed Dividends. An additional 13 and 12 shares were accumulated on April 1, 2007 and July 1, 2007, respectively.

9

IMAGE TECHNOLOGY LABORATORIES, INC.

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

The following is a discussion of certain factors affecting Image Technology Laboratories, Inc.'s results of operations, assets, liquidity and capital resources. You should read the following discussion and analysis in conjunction with Image Technology Laboratories, Inc.'s unaudited condensed financial statements and related notes, which are included elsewhere in this filing.

Image Technology Laboratories, Inc. ("we", "our" or the "Company") is a medical image and information management company in the healthcare information systems market. We were incorporated in Delaware on December 5, 1997. The Company has developed a single database "Radiology Information System and Picture Archiving and Communications System" known as RIS/PACS for use in the secure management of patient information and diagnostic images. Our lead product is the WarpSpeed system. Through its unique, modular architecture the Company has created a total radiology business solution that is readily scaled and easily upgraded. These features will allow the Company to provide products tailored to the size of its customers and to keep its customers at the forefront of future technological

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

advances by enabling the Company to easily update existing systems.

We expect that we will derive our future revenues primarily from sales of our WarpSpeed system and associated maintenance charges along with Application Service Provider (ASP) usage fees. We obtained our first contract for the sale of WarpSpeed and related hardware and maintenance services in August 2002. Accordingly, we are no longer in the development stage for accounting purposes, but we continue to refine and enhance the capabilities of our WarpSpeed system.

We have had recurring losses and negative cash flows from our operating activities since inception. We have cash of \$404,420 and a working capital of \$36,001 as of September 30, 2007.

10

IMAGE TECHNOLOGY LABORATORIES, INC.

RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2007 COMPARED WITH THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2006

REVENUE:

For the three months ended September 30, 2007, our total revenue was \$136,201, a increase of \$35,415 from the \$100,786 in the prior year's comparable period. For the nine months ended September 30, 2007, our total revenue was \$343,821, a \$180,928 decrease from the \$524,749 revenue in the prior year's comparable period, largely attributed to variations in the billed usage fees.

COST OF REVENUE:

For the three and nine months ended September 30, 2007, direct cost of revenue for \$4,209 and \$5,150 was incurred. For the three and nine months ending September 30, 2006, our cost of revenue was \$1,067 and \$2,017

SALES AND MARKETING EXPENSES:

During the three months ended September 30, 2007, we incurred sales and marketing expenses of \$4,154, as compared with sales and marketing expenses of \$3,788 during the same period of 2006, a increase of \$366. The Company has focused its efforts on controlling costs while identifying appropriate sales personnel and resources. These costs are expected to grow as the company executes its business plan. During the nine months ended September 30, 2007 we incurred sales and marketing expenses of \$11,518, as compared with sales and marketing expenses of \$13,278 during the same period of 2006, a decrease of \$1,760.

NET LOSS:

We incurred a net loss of \$115,326 (less than \$.01 per share) for the three months ended September 30, 2007 as compared with a loss of \$55,988 for the three months ended September 30, 2006. Net loss for the nine months ended September 30, 2007 was \$271,622 as compared with a net loss of \$77,300 for the same period in 2006 (less than \$.02 per share). The Company continues to aggressively manage costs while it focuses on increasing revenues from sales of systems / software.

11

IMAGE TECHNOLOGY LABORATORIES, INC.

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

LIQUIDITY AND CAPITAL RESOURCES

At September 30, 2007, our total assets were \$680,947, an increase of \$352,479 from total assets of \$328,468 on December 31, 2006.

As of September 30, 2007, we had cash and cash equivalents and a working capital of \$404,420 and \$36,001, respectively.

Net cash provided (used) in our operating activities for the 9 months ending September 30, 2007 of (\$98,527) was substantially attributable to our net loss of \$271,622, offset by \$8,488 in accrued compensation payable to stockholders. Of the net loss of \$271,622, \$73,448 was stock option compensation expense. The net cash used by our financing activities was a net of \$1,421 from our bank line of credit. The net cash provided from an Accounts Receivable loan was \$650,000. Investing activities (purchase of equipment and improvements) for the three months ending September 30, 2007 totaled \$79,702.

The foregoing activities, i.e., operating, investing and financing, resulted in our net cash increase of \$401,157 for the nine months ended September 30, 2007.

In September 2002, we applied for, and received, a line of credit from M & T Bank, renewable annually, in the amount of \$75,000. As of September 30, 2007, we have \$68,315 outstanding under that loan.

In February and March 2004, we borrowed an aggregate of \$264,000 from Valley Commercial Capital, LLC ("Valley"). These loans required aggregate monthly payments of principal and interest of \$8,273 through February 2007 and \$4,682 in March 2007. In late August 2006, the remaining balance of these loans, \$57,672, was paid. This payoff was funded by a loan from our largest stockholder and was converted to Cumulative Convertible Preferred Series B stock issued to our largest stockholder in late September 2006.

In December 2004, we borrowed \$105,000 from our former Chief Executive Officer, and were to be repaid over 24 months, beginning in January 2007. This amount was converted to Cumulative Convertible Preferred Series B stock issued to our largest stockholder in late September 2006.

In September 2005, the Company received a total of \$50,000 in cash as part of a Bridge Loan Agreement that included the issuance of warrants to purchase 50,000 shares of Common Stock of the Company. All \$50,000 of these funds came from a member of the Company's Board of Directors. The five-year warrants have an exercise price of \$0.33 per share. The Bridge Loan has an annual interest rate of 14%, a maturity of 12 months and can be prepaid upon certain events such as receipt of a certain level of funds from the InMed Services agreement and gross proceeds of equity financing above \$500,000. The principal of \$50,000 and part of the accrued interest were repaid in July 2007 and the remaining accrued interest of \$5,000 associated with this loan is still outstanding.

In December 2005, our largest stockholder loaned the Company an additional \$36,000 under an amendment to the December 2004 promissory note. An additional \$22,500 was borrowed from our largest stockholder in March 2006. These amounts were converted to Cumulative Convertible Preferred Series B stock issued to our largest stockholder in late September 2006.

In September 2006, the Company entered into a settlement agreement with Dr. Carlton Phelps, our former vice president of finance and administration, chief financial officer, secretary and treasurer. Pursuant to the Settlement Agreement, the Company paid Dr. Phelps a total of \$153,375 consisting of attorneys' fees awarded by the arbitrator and confirmed by the court plus interest calculated at a rate of nine percent per annum from September 4, 2004 until September 1, 2006. The Company filed an 8-K detailing this event with the

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

Securities and Exchange Commission on October 4, 2006. In September 2006, the Company's largest stockholder loaned the Company \$153,375, the proceeds of which were used to satisfy the \$153,375 settlement with Dr. Phelps. This amount was converted to Cumulative Convertible Preferred Series B stock issued to our largest stockholder in late September 2006.

12

IMAGE TECHNOLOGY LABORATORIES, INC.

In June 2007, the Company entered into a five-year Accounts Receivable loan agreement with PowerLease Solutions, LLC and NetBank to borrow \$650,000 at a 9.5% annual interest rate. Monthly payments are \$13,651 and the loan is co-signed by the Company's principal stockholder. As of September 30, 2007, there was \$624,281 outstanding under this agreement. Fixed fees payable to PowerLease were \$10,402.

We require cash to fund our working capital needs and capital expenditures, as well as to meet existing commitments. Such commitments include payments of existing loans including our line of credit, and \$900 per month pursuant to a five-year lease commitment ending in October 2007 for our operations center in Kingston, New York. At times, in order to help in maximizing our working capital, our directors, officers and employees have contributed to capital or deferred compensation due under their agreements. It is anticipated, but not assured, that, should the need arise; such contributions or deferrals might be available to us in the future. Additionally, we are considering outside sources of equity funds and other types of financing in order to help support our anticipated growth. There can be no assurance that such efforts will be successful.

Management believes that as a result of the proceeds from financing activities, as well as anticipated cash flow generated by sales of its RIS/PACS solution (in addition to the current cash flow resulting from our installed ASP base), the Company will be able to continue to meet its obligations as they become due through at least December 31, 2007. Management also believes, that if needed, the Company will be able to obtain additional capital resources from financing through financial institutions and other unrelated sources and/or through additional related party loans and private placements. However, there can be no assurance that the Company will become profitable or that financing will be available. Accordingly, the accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classification of liabilities that may result from the outcome of this uncertainty.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

In September 2005, the Company received a total of \$50,000 in cash as part of a Bridge Loan Agreement that included the issuance of warrants to purchase 50,000 shares of Common Stock of the Company. All \$50,000 of these funds came from a member of the Company's Board of Directors. The five-year warrants have an exercise price of \$0.33 per share. The Bridge Loan has an annual interest rate of 14%, a maturity of 12 months and can be prepaid upon certain events such as receipt of a certain level of funds from the InMed Services agreement and gross proceeds of equity financing above \$500,000. The principal of \$50,000 and half of the accrued interest were repaid in July 2007. The remaining accrued interest of \$5,000 associated with this loan is still outstanding.

In December 2005, the Estate of Dr. Ryon loaned the Company an additional \$36,000 under an amendment to the December 2004 promissory note. Additional amounts were loaned to the Company in March 2006 for \$22,500, in August 2006 for

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

\$57,672 and in September 2006 for \$153,375.26. These amounts, along with other previous loans to the Company by the largest stockholder totaling \$374,548 were converted to 1000 shares of Cumulative Convertible Preferred Series B stock in late September 2006, and all accrued interest was forgiven. Cumulative Convertible Preferred Stock Series B can be converted to common stock of Image Technology Laboratories at a ratio of one share of Cumulative Convertible Preferred Stock Series B to 2,700 shares of common stock. Either the stockholder or the Company may elect to force conversion after two years in units of 100 shares of Cumulative Convertible Preferred Stock Series B. The Company may also elect to repurchase the Cumulative Convertible Preferred Stock Series B in units of 100 shares of Cumulative Convertible Preferred Stock Series B at any time for \$432 per share of Cumulative Convertible Preferred Stock Series B. Fixed dividend is accumulated as 12.5 additional shares of Cumulative Convertible Preferred Stock Series B per quarter. The underlying common stock, should the Company or shareholder elect to convert, is unregistered. The voting rights are set at one vote per share of Cumulative Convertible Preferred Stock Series B.

13

IMAGE TECHNOLOGY LABORATORIES, INC.

On January 17 2006, Barry C. Muradian informed the Company of his resignation as President, Chief Executive Officer and Principal Accounting Officer, effective January 20 2006. An 8-K was filed with the Securities and Exchange Commission on January 20 2006. In May 2006, the Company and Mr. Muradian signed a "Confidential Separation Agreement, Waiver and General Release". As part of this agreement, Mr. Muradian was paid a total of approximately \$22,500, which represents all guaranteed payments due and owing to Mr. Muradian for salary and expenses.

In September 2006, the Company entered into a settlement agreement with Dr. Carlton Phelps, our former vice president of finance and administration, chief financial officer, secretary and treasurer. Pursuant to the Settlement Agreement, the Company paid Dr. Phelps a total of \$153,375 consisting of attorneys' fees awarded by the arbitrator and confirmed by the court plus interest calculated at a rate of nine percent per annum from September 4, 2004 until September 1, 2006. The Company filed an 8-K detailing this event with the Securities and Exchange Commission on October 4, 2006.

In September of 2006, the Company sold 2,309,583 shares of common stock at a price of \$0.10 to a group of seven accredited investors in a private placement under Section 4(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D there under. These unregistered shares of common stock were issued with registration rights. The proceeds of this sale of common stock were used to repurchase 2,309,583 shares of common stock at a price of \$0.10 from Dr. Carlton Phelps, our former vice president of finance, chief financial officer, secretary and treasurer. The 2,309,583 shares of stock repurchased from Dr. Phelps by the Company were cancelled upon their tender. An 8-K was filed with the Securities and Exchange Commission on October 4, 2006. The net effect of the repurchase and subsequent cancellation of 2,309,583 shares of common stock as described above in combination with the sale of 2,309,583 shares of common stock as described above resulted in no change to the number of shares of common stock outstanding due to this transaction

14

IMAGE TECHNOLOGY LABORATORIES, INC.

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

FORWARD-LOOKING STATEMENTS

When used in the Quarterly Report on Form 10-QSB, the words "may", "will", "should", "expect", "believe", "anticipate", "continue", "estimate", "project", "intend" and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act regarding events, conditions and financial trends that may affect our future plans of operations, business strategy, results of operations and financial condition. We wish to ensure that such statements are accompanied by meaningful cautionary statements pursuant to the safe harbor established in the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties and that actual results may differ materially from those included within the forward-looking statements as a result of various factors including our ability to consummate, and the terms of, acquisitions, if any. Such forward-looking statements should, therefore, be considered in light of various important factors, including those set forth herein and others set forth from time to time in our reports and registration statements filed with the Securities and Exchange Commission (the "Commission"). We disclaim any intent or obligation to update such forward-looking statements.

15

IMAGE TECHNOLOGY LABORATORIES, INC.

ITEM 3 - CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

Our Chief Technology Officer who is our Principal Accounting Officer, after evaluating the effectiveness of the Company's disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-14(c) and 15d-14(c) as of the end of the period covered by this report (the "Evaluation Date")), have concluded that as of the Evaluation Date, our disclosure controls and procedures were adequate and effective to ensure that material information relating to the Company would be made known to them by others within the Company, particularly during the period in which this quarterly report on Form 10-QSB was being prepared.

CHANGES IN INTERNAL CONTROLS

There were no significant changes in our internal controls or in other factors that could significantly affect our disclosure controls and procedures subsequent to the Evaluation Date, nor any significant deficiencies or material weaknesses in such disclosure controls and procedures requiring corrective actions. As a result, no corrective actions were taken.

16

IMAGE TECHNOLOGY LABORATORIES, INC.

PART II - OTHER INFORMATION

ITEM 1 - LEGAL PROCEEDINGS

None

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

ITEM 2 - CHANGES IN SECURITIES

The Company converted a total of \$374,548 of debt owed to our largest shareholder to 1000 shares of Image Technology Laboratories Cumulative Convertible Preferred Stock Series B issued to same stockholder in late September 2006. Cumulative Convertible Preferred Stock Series B can be converted to common stock of Image Technology Laboratories at a ratio of one share of Cumulative Convertible Preferred Stock Series B to 2,700 shares of common stock. Either the stockholder or the Company may elect to force conversion after two years in units of 100 shares of Cumulative Convertible Preferred Stock Series B. The Company may also elect to repurchase the Cumulative Convertible Preferred Stock Series B in units of 100 shares of Cumulative Convertible Preferred Stock Series B at any time for \$432 per share of Cumulative Convertible Preferred Stock Series B. Fixed dividend is accumulated as 12.5 additional shares of Cumulative Convertible Preferred Stock Series B per quarter. The underlying common stock, should the Company or stockholder elect to convert, is unregistered. The voting rights are set at one vote per share of Cumulative Convertible Preferred Stock Series B.

Our largest stockholder accumulated 12 additional shares of Cumulative Convertible Preferred Stock Series B on July 1, 2007 under the terms described above as Fixed Dividends.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 5 - OTHER INFORMATION

In April 2007, the Company executed an amendment to its contract with Park Avenue Associates in Radiology PC, Binghamton NY to extend the term of the original RIS/PACS contract through December 31, 2008 and for the purchase of additional equipment to provide internet / web access to their images and reports by referring physicians.

The Company was notified by its independent registered accounting firm, Berenson, LLP, that effective May 15, 2007 they were terminating their services to the Company as a result of a combination with the Company's prior independent registered accounting firm, J.H. Cohn, LLP. The Company subsequently filed an 8-K with the Securities and Exchange Commission on May 17, 2007. On June 22, 2005, the Board of Directors of the Company elected to discontinue its engagement of J.H. Cohn, LLP as the Company's independent registered accounting firm. The Company subsequently notified J.H. Cohn, LLP of its decision and filed a Form 8-K with the Securities and Exchange Commission on June 29, 2005.

17

IMAGE TECHNOLOGY LABORATORIES, INC.

In July 2007, the Company entered into a five year ASP contract with Bon Secours Community Hospital in Port Jervis, NY to install and maintain our WarpSpeed RIS / PACS solution, including HIS connectivity, failover capability via a secondary server and secure Web access.

ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K

Edgar Filing: IMAGE TECHNOLOGY LABORATORIES INC - Form 10QSB

(a) EXHIBITS.

31.1 Certification of Chief Technology Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 Certification of Chief Technology Officer and Principal Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(b) REPORTS ON FORM 8-K.

None.

18

IMAGE TECHNOLOGY LABORATORIES, INC.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

/S/ LEWIS M. EDWARDS

LEWIS M. EDWARDS,
CHAIRMAN,
EXECUTIVE VICE-PRESIDENT,
CHIEF TECHNOLOGY OFFICER, AND PRINCIPAL
ACCOUNTING OFFICER
NOVEMBER 20, 2007

19